# Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/neovascular-age-related-macular-degeneration-developing-drugs-for-treatment/3b32c08c-4e69-42f4-ba19-cda20a8af050

> FDA guidance document: Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment. Issue date: February 24, 2023. Get complete insights and analysis.

---

## Details

- Title: Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2023-02-24
- Comment Close Date: 2023-05-30
- Last Changed: 2023-03-03
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2022-D-0073">FDA-2022-D-0073</a>

## Related Documents

- [Master Protocols for Drug and Biological Product Development](https://www.globalkeysolutions.net/guidances/guidance-document/master-protocols-for-drug-and-biological-product-development/401e65ec-7388-4389-a95a-dc8860a1ce51)
- [Labeling for Biosimilar and Interchangeable Biosimilar Products](https://www.globalkeysolutions.net/guidances/guidance-document/labeling-for-biosimilar-and-interchangeable-biosimilar-products/54a5f712-03f5-4993-b0d7-6a1c2f261eff)
- [Fabry Disease: Developing Drugs for Treatment Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/fabry-disease-developing-drugs-for-treatment-guidance-for-industry/37d2e0fe-939f-490c-8fec-d2753a0f2f8c)